← Back to patent-cliff list
Risdiplam
Tier C — Watch / tradeRisdiplam
Ptc Therapeutics Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SMN
Brand：EVRYSDI
Indications (approved)：Spinal muscular atrophy
Regional status
US
Approved
2020-08-07
EU
Approved
2021-03-26
China
Approved
2021-06-16
Japan
Approved
2021-06-23
Factories producing this API1
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
1 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Risdiplam?
Approved indications include: Spinal muscular atrophy.
When does the Risdiplam patent expire?
No public expiry year is available for Risdiplam yet; this page updates once verified.
How do I get a quote for Risdiplam intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27